These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Treatment of acquired thrombotic thrombocytopenic purpura (TTP) with plasma infusion plus rituximab. Hagel S, Jantsch J, Budde U, Kalden JR, Eckardt KU, Veelken R. Thromb Haemost; 2008 Jul; 100(1):151-3. PubMed ID: 18612551 [No Abstract] [Full Text] [Related]
3. Recurrent thrombotic thrombocytopenic purpura treated repeatedly and successfully with the monoclonal antibody rituximab. Herbei L, Venugopal P. Clin Adv Hematol Oncol; 2006 Mar; 4(3):215-7; discussion 217-8. PubMed ID: 16728931 [No Abstract] [Full Text] [Related]
4. Rituximab as preventive therapy of a clinical relapse in TTP with ADAMTS13 inhibitor. Schleinitz N, Ebbo M, Mazodier K, Poullin P, Bernit E, Veit V, Veyradier A, Fakhouri F, Kaplanski G, Harle JR. Am J Hematol; 2007 May; 82(5):417-8. PubMed ID: 17266057 [No Abstract] [Full Text] [Related]
5. Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. Scully M, Cohen H, Cavenagh J, Benjamin S, Starke R, Killick S, Mackie I, Machin SJ. Br J Haematol; 2007 Feb; 136(3):451-61. PubMed ID: 17233847 [Abstract] [Full Text] [Related]
10. Rituximab prevents recurrence of thrombotic thrombocytopenic purpura: a case report. Galbusera M, Bresin E, Noris M, Gastoldi S, Belotti D, Capoferri C, Daina E, Perseghin P, Scheiflinger F, Fakhouri F, Grünfeld JP, Pogliani E, Remuzzi G. Blood; 2005 Aug 01; 106(3):925-8. PubMed ID: 15827129 [Abstract] [Full Text] [Related]
11. Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies. Bresin E, Gastoldi S, Daina E, Belotti D, Pogliani E, Perseghin P, Scalzulli PR, Paolini R, Marcenò R, Remuzzi G, Galbusera M. Thromb Haemost; 2009 Feb 01; 101(2):233-8. PubMed ID: 19190804 [Abstract] [Full Text] [Related]
12. Rituximab and intermediate-purity plasma-derived factor VIII concentrate (Koate®) as adjuncts to therapeutic plasma exchange for thrombotic thrombocytopenic purpura in patients with an ADAMTS13 inhibitor. Pandey S, Nakagawa M, Rosenbaum ER, Arnaoutakis K, Hutchins LF, Makhoul I, Milojkovic N, Cottler-Fox M. J Clin Apher; 2015 Feb 01; 30(1):50-4. PubMed ID: 25042026 [Abstract] [Full Text] [Related]
13. A Canadian phase II study evaluating the efficacy of rituximab in the management of patients with relapsed/refractory thrombotic thrombocytopenic purpura. Foley SR, Webert K, Arnold DM, Rock GA, Clark WF, Barth D, Sutton DM, Members of the Canada Apheresis Group (CAG). Kidney Int Suppl; 2009 Feb 01; (112):S55-8. PubMed ID: 19180138 [Abstract] [Full Text] [Related]
16. Effect of rituximab on B cell phenotype and serum B cell-activating factor levels in patients with thrombotic thrombocytopenic purpura. Becerra E, Scully MA, Leandro MJ, Heelas EO, Westwood JP, De La Torre I, Cambridge G. Clin Exp Immunol; 2015 Mar 01; 179(3):414-25. PubMed ID: 25339550 [Abstract] [Full Text] [Related]